Last reviewed 2026-05-29 · How we verify

Butobendin (BUTOBENDINE)

Phase 2 active Small molecule ✓ Verified May 2026

Butobendin (generic name: BUTOBENDINE) is a drug. It is currently in Phase 2 development.

Butobendin works by binding to a specific target, altering its function to produce a therapeutic effect.

Butobendin is a small molecule. It is also known by the synonyms Butobendina and Butobendine.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BUTOBENDINE
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of it like a key fitting into a lock. Butobendin is the key, and it fits into a specific lock on a target protein. This changes the way the protein works, which can help treat a particular condition.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Butobendin CI brief — competitive landscape report
Butobendin updates RSS · CI watch RSS

Frequently asked questions about Butobendin

What is Butobendin?

Butobendin (BUTOBENDINE) is a Small molecule drug.

How does Butobendin work?

Butobendin works by binding to a specific target, altering its function to produce a therapeutic effect.

What is the generic name of Butobendin?

BUTOBENDINE is the generic (nonproprietary) name of Butobendin.

What development phase is Butobendin in?

Butobendin is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing